Piper Sandler Increases Hims & Hers Health (NYSE:HIMS) Price Target to $13.00

Hims & Hers Health (NYSE:HIMS) had its price target increased by stock analysts at Piper Sandler from $11.00 to $13.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price target indicates a potential upside of 11.59% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group began coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. SVB Leerink began coverage on Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price on the stock. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Finally, Citigroup increased their target price on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Hims & Hers Health Price Performance

HIMS opened at $11.65 on Tuesday. The stock has a market cap of $2.50 billion, a P/E ratio of -105.91 and a beta of 0.97. The stock’s 50 day simple moving average is $14.01 and its 200 day simple moving average is $10.31. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company’s revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS. Research analysts expect that Hims & Hers Health will post 0.11 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 97,208 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Soleil Boughton sold 2,503 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the sale, the insider now directly owns 166,866 shares in the company, valued at approximately $2,611,452.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total value of $931,252.64. Following the sale, the chief executive officer now owns 51,653 shares of the company’s stock, valued at $494,835.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

Large investors have recently modified their holdings of the business. Graham Capital Management L.P. grew its stake in shares of Hims & Hers Health by 39.4% during the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after acquiring an additional 96,277 shares in the last quarter. Swiss National Bank grew its stake in shares of Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after acquiring an additional 26,100 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after purchasing an additional 58,288 shares in the last quarter. Finally, Must Asset Management Inc. acquired a new position in Hims & Hers Health in the third quarter worth about $1,596,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.